Clinical Trial Update: Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating whether olanzapine may influence outcomes when combined with first-line immunotherapy in advanced EGFR-negative non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• olanzapine (olanzapine)

Snippet

Sponsor: Second Affiliated Hospital of Nanchang University | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING